OBJECTIVE：To compare the efficacy and safety of desloratadine citrate disodium and acrivastine decremental therapy in the treatment of chronic urticaria. METHODS： 132 patients with chronic urticaria were randomly divided into group A （62 cases） and group B （70 cases）. Group A was orally given 8.8 mg Desloratadine citrate disodium tablet in 12 2 weeks， once a day； 8.8 mg in 3-4 weeks， once every 2 days； 8.8 mg in 5-6 weeks， once every 3 days； 8.8 mg in 7-8 weeks， once every 4 days； and 8.8 mg in 9-10 weeks， once every 5 days. Group B was orally given 8 mg Acrivastine capsule in 12 2 weeks， 3 times a day； 8 mg in 3-4 weeks， twice a day； 8 mg in 5-6 weeks， once a day； 8 mg in 7-8 weeks， once every 2 days； and 8 mg in 9-10 weeks， once every 3 days. The treatment course for both groups was 10 weeks. Clinical efficacy， and plasma histamine levels and total scores of signs and symptoms before and after treatment in 2 groups were observed， and recurrence and incidence of adverse reactions after 4 weeks of stopping drugs in 2 groups were followed-up. RESULTS： There were no significant difference in the total effective rate and incidence of adverse reactions between 2 groups（P＞0.05）. After treatment， the total scores of signs and symptoms in 2 groups were significantly lower than before， the difference was statistically significant（P＜0.01）， and there was no significant difference between 2 groups（P＞0.05）. The recurrence rate in group A was significantly lower than group B， the difference was statistically significant（P＜0.05）. CONCLUSIONS： Both efficacy and safety of desloratadine citrate disodium and acrivastine decremental therapy in the treatment of chronic urticaria are good， however， desloratadine citrate disodium is better than acrivastine in reducing recurrence rate.